Rimonabant 利莫那班;5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-N-(1-哌啶基)-1H-吡唑-3-甲酰胺;利莫纳班;利莫那班游离碱;5-Boc-4,5,6,7-四氢噻唑并[5,4-C]吡啶-2-甲酸;利莫那班（混合体）;利莫那班碱;食品级利莫那班;5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-N-(哌啶-1-基)-吡唑-3-甲酰胺

Rimonabant is a potent and selective cannabinoid (CB) receptor 1 antagonist (Ks = 5.6 and >1,000 nM for CB and CB, respectively). In rodent models, rimonabant induces lipolysis, reduces hepatomegaly, decreases body weight, and improves dyslipidemia by reducing triglyceride, free fatty acid, and total cholesterol levels and by increasing HDL/LDL ratios. Rimonabant elicits antiproliferative and immunomodulatory effects (e.g., cell cycle arrest, increased expression of IκB and phosphorylated Akt, and decreased expression of NF-κB, phosphorylated ERK1/2, COX-2, and iNOS) in vitro.